20 March 2017
Ribo rings up $39m
Suzhou Ribo Life Science, which is developing RNA therapies for hepatitis B, hyperlipidaemia and liver cancer, has secured funding in a Legend Capital-backed series B round.
Author: Robert Lavine, News Editor
China-based drug developer Suzhou Ribo Life Science has raised RMB270m ($39m) in a series B round that included Legend Capital, a subsidiary of conglomerate Legend Holdings, China Money Network reported on Friday.